PharmaTelevision - Artisan Draws Strength from Japan and the US to Treat Sepsis

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Artisan Draws Strength from Japan and the US to Treat Sepsis

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

Filmed at the BIO conference in San Diego, Fintan Walton talks to President and Chief Executive Officer of Artisan Pharma, Jeffrey D. Wager MD. Dr Jeffrey reveals how building close, long term relationships with Japanese companies has led to the formation of Artisan Pharma, a company funded by both Japanese and US investors. The company, based in Massachusetts, with the help of its partner, Asahi Kasei Pharma of Japan, was formed to create focus and attention around its lead product, ART-123 (Asahi recombinant thrombomodulin). A key to regulating thrombosis and inflammation, Dr Wager explains progress in the development and commercialisation of the product . The product is approved in Japan and used for the treatment of disseminated intravascular coagulation (DIC), including sepsis.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

The basis for founding of Artisan and role of Asahi Kasei Japan.

Fintan Walton:

Hello and welcome to pharmaventures business review here at Bio in San Diego. On this show I have Jeffrey D. Wager who is the president and CEO of Artisan Pharma based in Waltham, Massachusetts. Welcome to the show.

Jeffrey D. Wager:

Thanks very much.

Fintan Walton:

Jeff Artisan Pharma is a company that as I said is based in Massachusetts but it has a link to Japan.

Jeffrey D. Wager:

That's right.

Fintan Walton:

Could you tell us about that link and why that was the basis for a founding of Artisan.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Jeffrey D Wager

President and Chief Executive Officer

Dr. Jeffrey D. Wager senior management experience in the life sciences industry — spanning corporate development, venture capital, investment banking and drug development — dates back to 1990. He earned his medical degree from Rush Medical College and his MBA from the University of Chicago. From 1996-2006, Dr. Jeffrey D. Wager founded and grew Apeiron Partners LLC, a boutique life sciences investment bank. There, he raised over $275 million in capital for a wide variety of life sciences clients and completed five corporate spin-outs, including Targacept(NASDAQ: TRGT), QED Solutions and KBI BioPharma (from Kinetic Biosystems). He was also advisor to Z-Cube s.r.l., a $60 million venture capital arm of Zambon Group S.p.a., where he assisted in the founding of Suppremol GmbH, Elagen and other companies. From 1995-2000, Dr. Jeffrey D. Wager was also a Senior Associate at Medical Science Partners (MSP), a Harvard-sponsored venture capital fund. There, he was involved in the business development of companies such as ICAgen (NASDAQ: ICGN), ZYCOS, Diatide and deCODE Genetics (NASDAQ: DCGN). From 1991-1995, Dr. Jeffrey D. Wager was Executive Director, Business Development of a $1.4 billion Japanese trading company affiliate of the Bank of Tokyo, where he managed a number of major clinical studies sponsored by Japanese pharmaceutical companies and structured strategic alliances.

Artisan

Artisan Pharma is a U.S. biotechnology company formed in 2006 as a partnership between a group of Asian and Western investors led by NGN Capital and Asahi Kasei Pharma Corporation(AKP) . Their lead product, ART-123, is a late-stage biologic drug candidate in-licensed from AKP. A new, separate, independent entity, Artisan has a mission to become a leading critical-care pharmaceutical company. By blending a high degree of skill with world-class R&D, corporate development and operational competencies, the company aims to generate the maximum benefit to patients and the maximum value to its shareholders.